Rare, Threatened and Endangered Vascular Plants in Oregon: An Interim Report

This report on rare, threatened and endangered vascular plants in Oregon is a basic document in the process of inventorying the state\u27s natural areas * Prerequisite to the orderly establishment of natural preserves for research and conservation in Oregon are (1) a classification of the ecological types, and (2) a listing of the special organisms, which should be represented in a comprehensive system of designated natural areas. The necessary ecological classification was published in the U.S. Forest Service Pacific Northwest Forest and Range Experiment Station document, Research Natural Area Needs in the Pacific Northwest, by Dyrness et al. (1975). This valuable reference also provided lists of vascular plants of special interest in each major physiographic province, based on early work by Chambers and Siddall. Under the direction of the Oregon Rare and Endangered Plant Species Taskforce, work has actively continued to expand and perfect the list of vascular plant species, to serve the needs of land management and natural area planning in Oregon, and of many other governmental and private activities. Studies of rare and endangered plants in Oregon have involved a unique coalition of professional and amateur botanists, who have systematically gathered data on the distribution, abundance, habitat, and ecological requirements of some 700 native species. Coordination and leadership have come from the Oregon Rare and Endangered Plant Species Taskforce, and specifically from the Taskforce chairman, Jean L. Siddall. The Natural Area Preserves Advisory Committee has long recognized the significance of this effort and has encouraged the Taskforce\u27s goal of assembling a list of rare, threatened and endangered plant species for the State of Oregon. In August,1979, it was decided to support the publication of an interim report, summarizing the present status of all the plants under review by the Taskforce. This list will serve as a working document for the many individuals and organizations, both public and private, needing information on the rare plants in Oregon. This list will be particularly useful to the Natural Heritage Advisory Council (replacing the Natural Area Preserves Advisory Committee) as it develops the Natural Heritage Plan required by Oregon statute. Ultimately, a detailed Oregon List of Rare, Threatened and Endangered Plants will be produced. This current interim report is a timely step toward this goal

Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial

Background: Intensive antiplatelet therapy with three agents might be more effective than guideline treatment for preventing recurrent events in patients with acute cerebral ischaemia. We aimed to compare the safety and efficacy of intensive antiplatelet therapy (combined aspirin, clopidogrel, and dipyridamole) with that of guideline-based antiplatelet therapy. Methods: We did an international, prospective, randomised, open-label, blinded-endpoint trial in adult participants with ischaemic stroke or transient ischaemic attack (TIA) within 48 h of onset. Participants were assigned in a 1:1 ratio using computer randomisation to receive loading doses and then 30 days of intensive antiplatelet therapy (combined aspirin 75 mg, clopidogrel 75 mg, and dipyridamole 200 mg twice daily) or guideline-based therapy (comprising either clopidogrel alone or combined aspirin and dipyridamole). Randomisation was stratified by country and index event, and minimised with prognostic baseline factors, medication use, time to randomisation, stroke-related factors, and thrombolysis. The ordinal primary outcome was the combined incidence and severity of any recurrent stroke (ischaemic or haemorrhagic; assessed using the modified Rankin Scale) or TIA within 90 days, as assessed by central telephone follow-up with masking to treatment assignment, and analysed by intention to treat. This trial is registered with the ISRCTN registry, number ISRCTN47823388. Findings: 3096 participants (1556 in the intensive antiplatelet therapy group, 1540 in the guideline antiplatelet therapy group) were recruited from 106 hospitals in four countries between April 7, 2009, and March 18, 2016. The trial was stopped early on the recommendation of the data monitoring committee. The incidence and severity of recurrent stroke or TIA did not differ between intensive and guideline therapy (93 [6%] participants vs 105 [7%]; adjusted common odds ratio [cOR] 0·90, 95% CI 0·67–1·20, p=0·47). By contrast, intensive antiplatelet therapy was associated with more, and more severe, bleeding (adjusted cOR 2·54, 95% CI 2·05–3·16, p<0·0001). Interpretation: Among patients with recent cerebral ischaemia, intensive antiplatelet therapy did not reduce the incidence and severity of recurrent stroke or TIA, but did significantly increase the risk of major bleeding. Triple antiplatelet therapy should not be used in routine clinical practice

Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial

Background: Intensive antiplatelet therapy with three agents might be more effective than guideline treatment for preventing recurrent events in patients with acute cerebral ischaemia. We aimed to compare the safety and efficacy of intensive antiplatelet therapy (combined aspirin, clopidogrel, and dipyridamole) with that of guideline-based antiplatelet therapy.Methods: We did an international, prospective, randomised, open-label, blinded-endpoint trial in adult participants with ischaemic stroke or transient ischaemic attack (TIA) within 48 h of onset. Participants were assigned in a 1:1 ratio using computer randomisation to receive loading doses and then 30 days of intensive antiplatelet therapy (combined aspirin 75 mg, clopidogrel 75 mg, and dipyridamole 200 mg twice daily) or guideline-based therapy (comprising either clopidogrel alone or combined aspirin and dipyridamole). Randomisation was stratified by country and index event, and minimised with prognostic baseline factors, medication use, time to randomisation, stroke-related factors, and thrombolysis. The ordinal primary outcome was the combined incidence and severity of any recurrent stroke (ischaemic or haemorrhagic; assessed using the modified Rankin Scale) or TIA within 90 days, as assessed by central telephone follow-up with masking to treatment assignment, and analysed by intention to treat. This trial is registered with the ISRCTN registry, number ISRCTN47823388.Findings: 3096 participants (1556 in the intensive antiplatelet therapy group, 1540 in the guideline antiplatelet therapy group) were recruited from 106 hospitals in four countries between April 7, 2009, and March 18, 2016. The trial was stopped early on the recommendation of the data monitoring committee. The incidence and severity of recurrent stroke or TIA did not differ between intensive and guideline therapy (93 [6%] participants vs 105 [7%]; adjusted common odds ratio [cOR] 0·90, 95% CI 0·67–1·20, p=0·47). By contrast, intensive antiplatelet therapy was associated with more, and more severe, bleeding (adjusted cOR 2·54, 95% CI 2·05–3·16,

Steens Mountain

Volume: 19Start Page: 91End Page: 9

Saxifragia eschscholtzii Sternb

Volume: 17Start Page: 203End Page: 20

Pitfalls in Identifying Ventenata dubia (Poaceae)

Volume: 32Start Page: 120End Page: 12

Notes on the Flora of Clatsop County, Oregon

Volume: 22Start Page: 278End Page: 27

The Taxonomic Relationships of Allocarya corallicarpa (Boraginaceae)

Volume: 36Start Page: 280End Page: 28

CORRIGENDA: A NEW SPECIES OF ERIGERON (ASTERACEAE) FROM SOUTHWESTERN OREGON

Volume: 6Start Page: 129End Page: 12

INFRAGENERIC CLASSIFICATION AND NOMENCLATURAL NOTES FOR PYCNANTHEMUM (LAMIACEAE)

Volume: 2Start Page: 193End Page: 19